Telix Pharmaceuticals Limited is a clinical-stage biotechnology company dedicated to the development and commercialisation of molecularly-targeted radiation (MTR) therapy. Our products seek to address major clinical unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer.
Our mission is
to help patients
with cancer live longer
with better quality lives
Thank you to @ScottPowerSays from @morgansAU for the shout-out during his @Bloomberg Radio interview today. Yes, the Australian biotech landscape has plenty of potential and $TLX is proud to be a key part of it.